NeuroSense Therapeutics (NeuroSense Therapeutics) Accounts Payable & Accrued Expense : $3.18 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Accounts Payable & Accrued Expense?

NeuroSense Therapeutics's quarterly accounts payable & accrued expense declined from Jun. 2023 ($3.01 Mil) to Sep. 2023 ($2.81 Mil) but then increased from Sep. 2023 ($2.81 Mil) to Dec. 2023 ($3.18 Mil).

NeuroSense Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 ($0.60 Mil) to Dec. 2022 ($1.29 Mil) and increased from Dec. 2022 ($1.29 Mil) to Dec. 2023 ($3.18 Mil).

NeuroSense Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for NeuroSense Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Accounts Payable & Accrued Expense Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

0.04

0.12

0.60

1.29

3.18

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										1.29	1.79	3.01	2.81	3.18

NeuroSense Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NRSN:USA

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.